1. "2011"
Formats
  1. Journal Article (2141)
  2. Meeting Abstract (988)
  3. Book Section (224)
  4. Conference Paper (18)
  5. Book Whole (11)
Groups
  1. Department of Medicine (1176)
  2. Surgery (803)
  3. GSK Faculty (796)
  4. Solid Tumor Oncology Division (659)
  5. Sloan Kettering Institute Faculty (606)
  6. Survivorship Research (542)

More Groups

People
  1. Robert Soslow (64)
  2. Clifford Hudis (60)
  3. Mithat Gonen (54)
  4. Marc Ladanyi (52)
  5. Robert Motzer (52)
  6. Valerie Rusch (47)

More People

Years
  1. 2011 (3382)
Publications
  1. Journal of Clinical Oncology (319)
  2. Blood (147)
  3. Cancer Research (122)
  4. International Journal of Radiation Oncology, Biology, Physics (104)
  5. Modern Pathology (70)
  6. Laboratory Investigation (65)

More Publications

Publishers
  1. Elsevier Inc. (450)
  2. American Society of Clinical Oncology (327)
  3. Springer (231)
  4. American Association for Cancer Research (180)
  5. Nature Publishing Group (157)
  6. Wiley Blackwell (154)

More Publishers

Results (3382)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The knowledge and practices of urologists in the United States (US) about standardization of PSA assays
    Meeting Abstract

    Gupta, A.; Shariat, S. F.; Eastham, J. A.; Scardino, P. T.; Vickers, A. J.; Lilja, H.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Defining "cisplatin ineligible" patients with metastatic bladder cancer
    Meeting Abstract

    Galsky, M. D.; Hahn, N. M.; Rosenberg, J. E.; Sonpavde, G.; Oh, W. K.; Dreicer, R.; Vogelzang, N. J.; Sternberg, C. N.; Bajorin, D. F.; Bellmunt, J.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)
    Meeting Abstract

    Halabi, S.; Kelly, W. K.; George, D. J.; Morris, M. J.; Kaplan, E. B.; Small, E. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study
    Meeting Abstract

    Higano, C. S.; Beer, T. M.; Taplin, M.; Efstathiou, E.; Anand, A.; Hirmand, M.; Fleisher, M.; Scher, H. I.; for the Prostate Cancer Clinical Trials Consortium
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy
    Meeting Abstract

    Hutson, T. E.; Bracarda, S.; Escudier, B.; Porta, C.; Figlin, R. A.; Calvo, E.; Grunwald, V.; Ravaud, A.; Kpamegan, E.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Clinicopathologic findings in Jamaican men with prostate cancer
    Meeting Abstract

    Kampel, L. J.; Tse, K.; Joseph, M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Genomic analysis of circulating tumor cells to evaluate predictive biomarkers
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Fleisher, M.; Sawyers, C. L.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Hand-foot skin reaction, an anticipated dermatologic toxicity to pazopanib, with an unexpected low incidence: A systematic review of literature and meta-analysis
    Meeting Abstract

    Balagula, Y.; Wu, S.; Su, X.; Lacouture, M. E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I
    Meeting Abstract

    Feifer, A.; Taylor, J. M.; Shouery, M.; Steinberg, G. D.; Stadler, W. M.; Schoenberg, M.; Zlotta, A.; Lerner, S. P.; Bajorin, D. F.; Bochner, B.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study
    Meeting Abstract

    Figlin, R. A.; Calvo, E.; Motzer, R. J.; Hutson, T. E.; Oudard, S.; Porta, C.; Grunwald, V.; Ravaud, A.; Kpamegan, E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save